CELLETS® 150-300 – a size of a sphere

In the realm of pharmaceutical formulations, researchers continuously seek efficient and reliable drug delivery systems. As a result, significant advancements have emerged. Among these, CELLETS®—highly spherical microcrystalline cellulose (MCC) pellets—play a pivotal role in developing multiparticulate oral dosage forms. Moreover, these neutral starter cores provide a versatile platform for layering and coating active pharmaceutical ingredients (APIs). Consequently, they enable controlled and sustained drug release.

Understanding Pellet Technologies

Pellet technologies involve using starter pellets as excipients in pharmaceutical formulations. These pellets act as carriers for APIs and other excipients. Consequently, they facilitate the creation of modern drug formulations with defined release profiles or taste-masking properties. The process includes coating and layering APIs onto the starter spheres. This approach results in formulations that offer various therapeutic benefits and improve patient compliance. Therefore, pellet size is crucial for the final dosage form.

Thus, pellet technology opens the door to multiparticulate dosage forms. Next, we will explore the intriguing benefits of these modern formulations.

Technical information

  • Particle Size: Camsizer (D10/D50/D90): NLT 170 / 205-275 / NMT 295
  • Composition: 100% microcrystalline cellulose
  • Applications: Neutral starter cores for modified-release formulations of highly active or low-concentration APIs
Get your sample here

Celphere CP 203 alternative MCC pellet sphere supply chain

Advantages of Multiparticulate Dosage Forms

Multiparticulate dosage forms, such as those employing CELLETS®, present several advantages over traditional monolithic systems:

  • Enhanced Safety:

    The distribution of APIs across multiple pellets reduces the risk of localized high drug concentrations in the gastrointestinal tract, minimizing potential side effects, such as risk of sudden dose dumping or the variability of gastric emptying.

  • Improved Compliance:

    Controlled release profiles can lead to reduced dosing frequency, enhancing patient adherence to medication regimens. This might also include simplification on drug uptake as it lowers the dependency on the nutrition state.

  • Flexible Formulation:

    The ability to combine pellets with different release characteristics allows for tailored therapeutic outcomes, addressing specific patient needs. Thus, a suitable formulation allows high control on time and place of drug delivery.

Advancements in CELLETS® for Pharmaceutical Formulations

CELLETS® have undergone continuous development to meet the evolving demands of pharmaceutical formulations:

  • Chemical Inertness:

    CELLETS®, made from 100% microcrystalline cellulose, remain chemically inert, which prevents interactions with APIs and preserves the stability and efficacy of the drug. In addition, this chemical inertness allows for safer handling in patients with metabolic disorders, as MCC contains no protein, fat, carbohydrate, sugar, or salt according to its nutritional table.

  • Mechanical Stability:

    The specific manufacturing process gives CELLETS® high mechanical stability, resulting in low friability. Consequently, this robustness enables more efficient layering and coating processes, which improves production yields. Moreover, the combination of mechanical strength and uniformity ensures consistent performance throughout manufacturing.

  • High Sphericity and Smooth Surface:

    Furthermore, the uniform spherical shape and smooth surface of CELLETS® allow for consistent coating applications, which in turn produce predictable and reproducible drug release profiles.

Clearly, the almost infinite variety of pharmaceutical formulations, drug release profiles and applicant targeted benefits require flexibility at the very first point of decision: which pellet size suits best? Answer: it depends. Consequently, suppliers of pharmaceutical pellets offer a portfolio of different pellet sizes.

A bunch of sizes

CELLETS® are available in various size fractions to cater to specific formulation requirements. Technical specifications range from 100 µm for CELLETS® 100 to 1000 µm and larger for CELLETS® 1000.

Small pellets are suitable for formulations that require a balance between surface area and pellet size. They facilitate controlled drug release. These tiny pellets are frequently used in jellies, gels, or multiple-unit particle systems (MUPS). In contrast, large pellets above 700 µm are preferred when a larger size is advantageous. For example, they support specific controlled-release profiles or a higher API payload. Large pellets are commonly used in capsules or straws, among other applications. Mid-sized pellets represent the major class, and a single general statement cannot describe their dedicated dosage forms.

Importantly, decreasing pellet size increases the surface-to-volume ratio in a formulation. Formulation experts use this fact to adjust the drug layering surface within a dosage unit. This approach ensures optimal benefits for the desired drug release profile. Leading pellet suppliers, such as IPC Process Center (Dresden, Germany), recognized this demand. They offer various pellet sizes with wide and narrow particle size distributions.

Within the mid-sized class, ingredientpharm introduces a new pellet type, covering 150 µm to 300 µm. Size specifications rely on laser diffraction methods, which are globally recognized and accepted. The D-values are defined as D10/D50/D90: NLT 170 / 205–275 / NMT 295.

CELLETS® 150-300

  • Particle Size: 150–300 µm. Camsizer (D10/D50/D90): NLT 170 / 205-275 / NMT 295
  • Composition: 100% microcrystalline cellulose
  • Appearance: White to off-white, hard, and nearly spherical particles
  • Applications: Ideal for extended-release formulations of highly active or low-concentration APIs, serving as neutral starter cores and multiparticulate carriers.

Conclusion

CELLETS® 150–300 are a sphere size in high demand for pharmaceutical formulations. Their integration demonstrates the progress in pellet technologies. These MCC pellets have unique physico-chemical properties, including chemical inertness, mechanical stability, and precise size distribution. Therefore, they are indispensable for developing safe, effective, and patient-friendly drug delivery systems. As pharmaceutical markets evolve, CELLETS® provide a reliable foundation for innovative dosage forms. With the new CELLETS® 150–300, a highly requested particle size is now available for experts in modern extended-release formulations.

Do you like to see sampling units of CELLETS® 150-300 in your R&D labs? Let’s talk about or simply order here.

CELLETS 150-300 are Celphere CP 203 alternative MCC pellets spheres made in Germany